A Multi-Centre, Open-Label, Randomised Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer
Phase of Trial: Phase III
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Registrational
- Sponsors Ferring Pharmaceuticals
- 03 Jul 2017 Status changed from active, no longer recruiting to completed.
- 07 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 11 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.